China Approves Lilly's Oral Orforglipron; Hims Deal Adds Zepbound Access
LLY sits 70% above its 52-week low of $850.51.
Summary
China approved orforglipron, Lilly's oral GLP-1, making it the first such filing cleared in the country while Novo's oral Wegovy remains unapproved there. That gives Lilly first-mover status in an oral obesity market where it currently only competes with injectables. Separately, Lilly struck a deal with Hims & Hers to widen access to Zepbound and Foundayo for eligible patients, with the platform committing not to sell compounded copies of Lilly's GLP-1s — a channel win that also squeezes copycat supply. On the risk side, Trulicity and Verzenio are in Medicare's latest price talks, with CMS due to announce negotiated prices by November 30 and new prices taking effect in 2028. New Phase 3b data showed Taltz plus Zepbound hit ACR50 and at least 10% weight loss in 39.2% of psoriatic arthritis patients versus 1.7% on Taltz alone, supporting label expansion. The stock is near its 52-week high, so the Medicare price announcement by November 30 is the near-term swing factor.
At the time of this announcement, LLY was trading at $1,447.85 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.4T. The 52-week trading range was $850.51 to $1,453.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.